Arbutus's Imdusiran Combined With Short-Term Interferon Successfully Maintains Undetectable HBsAg Levels, Essential For A Functional Cure Of HBV
Portfolio Pulse from Benzinga Newsdesk
Arbutus's imdusiran combined with short-term interferon successfully maintains undetectable HBsAg levels, essential for a functional cure of HBV. 33.3% of patients achieved undetectable HBsAg levels, maintained in 100% of these patients 24 weeks post-treatment. Six patients have undetectable HBsAg and HBV DNA after stopping all therapy.
June 05, 2024 | 7:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arbutus's imdusiran combined with short-term interferon shows promising results in maintaining undetectable HBsAg levels, crucial for a functional HBV cure. This could positively impact Arbutus's stock price.
The successful Phase 2a data presented at the EASL Congress 2024 indicates that Arbutus's imdusiran, combined with short-term interferon, is effective in maintaining undetectable HBsAg levels. This is a significant milestone for a functional cure of HBV, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100